Wall Street ends mixed as investors eye earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Intel (INTC) PT Raised to $54 at RBC Capital Into Print; Sees Upside
April 24, 2018 1:29 PM EDTRBC Capital analyst Amit Daryanani raised his price target on Intel (NASDAQ: INTC) to $54.00 (from $46.00) while maintaining a Sector Perform rating ahead of results on April 26. Daryanani sees Intel well positioned for upside.
"We expect INTC to print upside vs. consensus... More
Merck (MRK) Reports EMA Validation of Type II Variation for KEYTRUDA (pembrolizumab) in Combination with Pemetrexed (ALIMTA) and Platinum Chemotherapy
April 23, 2018 4:35 PM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the companys Type II Variation, which seeks approval for KEYTRUDA, Mercks anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy (cisplatin or carboplatin) for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC). The application was accepted for review based on overall survival (OS) and progression-free survival (PFS) data from the Phase 3 KEYNOTE-189 trial, which were recently... More
Stifel Remains Sidelined on Facebook (FB) Ahead of 1Q Release
April 23, 2018 8:27 AM EDTStifel reiterated a Hold rating and $168.00 price target on Facebook (NASDAQ: FB) ahead of the company's 1Q earnings report. Analyst Scott Devitt forecasts 1Q revenue to increase +42% y/y to ~$11.43B (versus the Streets estimate of $11.41B), with ad revenue increasing +43%... More
